Open Payments

Kfh - Antioch

Type
Teaching hospital
Where
Antioch, CA
Medicare CCN
050760
Received
$3,665,554 in 215 records, 2023 ($194 general, $3,665,360 research)
Source
CMS Open Payments search ↗

By year

Program yearKindRecordsAmount
2023General payment1$194
2023Research payment214$3,665,360

By company

CompanyRecordsAmountYears
PFIZER INC.151$2,010,3952023
Genentech, Inc.63$1,654,9652023
Cochlear Americas1$1942023

By nature of payment

NatureRecordsAmount
Research payment214$3,665,360
Long term medical supply or device loan1$194

Records

DateCompanyAmountNatureFormProductStudyYear
2023-12-27PFIZER INC.$2,400Research paymentCash or cash equivalentCOMIRNATY Biological, VACCINESPHASE 1 OPENLABEL DOSEFINDING STUDY TO EVALUATE SAFETY TOLERABILITY AND IMMUNOGENICITY AND PHASE 23 PLACEBOCONTROLLED OB2023
2023-12-26PFIZER INC.$15,514Research paymentCash or cash equivalentA PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED2023
2023-12-23PFIZER INC.$750Research paymentCash or cash equivalentABRYSVO Biological, VACCINESA PHASE 3 STUDY TO EVALUATE THE EFFICACY IMMUNOGENICITY AND SAFETY OF RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNI2023
2023-12-22PFIZER INC.$26,091Research paymentCash or cash equivalentPREVNAR 20 Biological, VACCINESA PHASE 4 STUDY USING A TESTNEGATIVE DESIGN TO EVALUATE THE EFFECTIVENESS OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE A2023
2023-12-21PFIZER INC.$4,677Research paymentCash or cash equivalentPREVNAR 20 Biological, VACCINESA PHASE 4 STUDY USING A TESTNEGATIVE DESIGN TO EVALUATE THE EFFECTIVENESS OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE A2023
2023-12-21Genentech, Inc.$4,342Research paymentCash or cash equivalentGazyva Biological, BioOncologyGazyva for the treatment of MN2023
2023-12-20PFIZER INC.$5,000Research paymentCash or cash equivalentA PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED2023
2023-12-12PFIZER INC.$1,200Research paymentCash or cash equivalentCOMIRNATY Biological, VACCINESPHASE 1 OPENLABEL DOSEFINDING STUDY TO EVALUATE SAFETY TOLERABILITY AND IMMUNOGENICITY AND PHASE 23 PLACEBOCONTROLLED OB2023
2023-12-08PFIZER INC.$750Research paymentCash or cash equivalentCOMIRNATY Biological, VACCINESAN INTERVENTIONAL RANDOMIZED ACTIVECONTROLLED PHASE 23 STUDY TO INVESTIGATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY O2023
2023-12-07PFIZER INC.$27,684Research paymentCash or cash equivalentPREVNAR 20 Biological, VACCINESA PHASE 4 STUDY USING A TESTNEGATIVE DESIGN TO EVALUATE THE EFFECTIVENESS OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE A2023
2023-12-06PFIZER INC.$3,600Research paymentCash or cash equivalentCOMIRNATY Biological, VACCINESA PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENIC2023
2023-12-06PFIZER INC.$1,343Research paymentCash or cash equivalentPREVNAR 20 Biological, VACCINESA PHASE 4 STUDY USING A TESTNEGATIVE DESIGN TO EVALUATE THE EFFECTIVENESS OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE A2023
2023-11-25PFIZER INC.$31,442Research paymentCash or cash equivalentPREVNAR 20 Biological, VACCINESA PHASE 4 STUDY USING A TESTNEGATIVE DESIGN TO EVALUATE THE EFFECTIVENESS OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE A2023
2023-11-24PFIZER INC.$4,677Research paymentCash or cash equivalentPREVNAR 20 Biological, VACCINESA PHASE 4 STUDY USING A TESTNEGATIVE DESIGN TO EVALUATE THE EFFECTIVENESS OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE A2023
2023-11-21PFIZER INC.$2,500Research paymentCash or cash equivalentABRYSVO Biological, VACCINESA PHASE 3 STUDY TO EVALUATE THE EFFICACY IMMUNOGENICITY AND SAFETY OF RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNI2023
2023-11-15Cochlear Americas$194Long term medical supply or device loanIn-kind items and servicesCOCHLEAR NUCLEUS CI632 COCHLEAR IMPLANT WITH SLIM MODIOLAR ELECTRODE Device, Implantable hearing solution2023
2023-11-14PFIZER INC.$500Research paymentCash or cash equivalentABRYSVO Biological, VACCINESA PHASE 3 STUDY TO EVALUATE THE EFFICACY IMMUNOGENICITY AND SAFETY OF RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNI2023
2023-11-13Genentech, Inc.$582Research paymentCash or cash equivalentHerceptin Biological, BioOncologyChemo trastuzumab vs chemo trastuzumab pertuzumab2023
2023-11-09PFIZER INC.$1,500Research paymentCash or cash equivalentCOMIRNATY Biological, VACCINESA PHASE 3 MASTER PROTOCOL TO EVALUATE ADDITIONAL DOSES OF BNT162B2 IN HEALTHY INDIVIDUALS PREVIOUSLY VACCINATED WITH BNT2023
2023-11-04PFIZER INC.$10,161Research paymentCash or cash equivalentPREVNAR 20 Biological, VACCINESA PHASE 4 STUDY USING A TESTNEGATIVE DESIGN TO EVALUATE THE EFFECTIVENESS OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE A2023
2023-11-04PFIZER INC.$2,500Research paymentCash or cash equivalentCOMIRNATY Biological, VACCINESAN INTERVENTIONAL RANDOMIZED ACTIVECONTROLLED PHASE 23 STUDY TO INVESTIGATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY O2023
2023-10-30Genentech, Inc.$5,564Research paymentCash or cash equivalentA phase III trial of GDC 9545 in combination with palbo in HR HER2 neg 1L mBC2023
2023-10-30Genentech, Inc.$524Research paymentCash or cash equivalentA phase III trial of GDC 9545 in combination with palbo in HR HER2 neg 1L mBC2023
2023-10-27Genentech, Inc.$5,356Research paymentCash or cash equivalentSingle agent GDC 9545 vs endocrine monotherapy adjuvant treatment in HR eBC2023
2023-10-26PFIZER INC.$6,000Research paymentCash or cash equivalentABRYSVO Biological, VACCINESA PHASE 3 STUDY TO EVALUATE THE EFFICACY IMMUNOGENICITY AND SAFETY OF RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNI2023
2023-10-26Genentech, Inc.$1,073Research paymentCash or cash equivalentCellCept Drug, Virology & Specialty CareRandomised Double blind study to evaluate safety and efficacy of Obinutuzumab in Class III and IV LN2023
2023-10-24PFIZER INC.$21,343Research paymentCash or cash equivalentPREVNAR 20 Biological, VACCINESA PHASE 4 STUDY USING A TESTNEGATIVE DESIGN TO EVALUATE THE EFFECTIVENESS OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE A2023
2023-10-21PFIZER INC.$4,887Research paymentCash or cash equivalentABRYSVO Biological, VACCINESA PHASE 3 STUDY TO EVALUATE THE EFFICACY IMMUNOGENICITY AND SAFETY OF RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNI2023
2023-10-21PFIZER INC.$1,243Research paymentCash or cash equivalentPREVNAR 20 Biological, VACCINESA PHASE 4 STUDY USING A TESTNEGATIVE DESIGN TO EVALUATE THE EFFECTIVENESS OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE A2023
2023-10-17PFIZER INC.$500Research paymentCash or cash equivalentA PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED2023
2023-10-13PFIZER INC.$500Research paymentCash or cash equivalentA PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED2023
2023-10-11PFIZER INC.$18,729Research paymentCash or cash equivalentPREVNAR 20 Biological, VACCINESA PHASE 4 STUDY USING A TESTNEGATIVE DESIGN TO EVALUATE THE EFFECTIVENESS OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE A2023
2023-10-11PFIZER INC.$2,446Research paymentCash or cash equivalentLITFULO Drug, IMMUNOLOGYA PHASE 3 OPENLABEL MULTICENTER LONGTERM STUDY INVESTIGATING THE SAFETY AND EFFICACY OF PF06651600 IN ADULT AND ADOLESCE2023
2023-10-10PFIZER INC.$2,486Research paymentCash or cash equivalentPREVNAR 20 Biological, VACCINESA PHASE 4 STUDY USING A TESTNEGATIVE DESIGN TO EVALUATE THE EFFECTIVENESS OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE A2023
2023-10-04PFIZER INC.$7,000Research paymentCash or cash equivalentCOMIRNATY Biological, VACCINESPHASE 1 OPENLABEL DOSEFINDING STUDY TO EVALUATE SAFETY TOLERABILITY AND IMMUNOGENICITY AND PHASE 23 PLACEBOCONTROLLED OB2023
2023-10-04PFIZER INC.$7,000Research paymentCash or cash equivalentCOMIRNATY Biological, VACCINESPHASE 1 OPENLABEL DOSEFINDING STUDY TO EVALUATE SAFETY TOLERABILITY AND IMMUNOGENICITY AND PHASE 23 PLACEBOCONTROLLED OB2023
2023-10-04PFIZER INC.$6,661Research paymentCash or cash equivalentCOMIRNATY Biological, VACCINESPHASE 1 OPENLABEL DOSEFINDING STUDY TO EVALUATE SAFETY TOLERABILITY AND IMMUNOGENICITY AND PHASE 23 PLACEBOCONTROLLED OB2023
2023-09-28PFIZER INC.$329,968Research paymentCash or cash equivalentIBRANCE Drug, ONCOLOGYCLINICAL CHARACTERISTICS TREATMENT PATTERNS AND OUTCOMES AMONG PATIENTS WITH HRHER2 BREAST CANCER IN THE UNITED STATES2023
2023-09-28Genentech, Inc.$1,087Research paymentCash or cash equivalentGazyva Biological, BioOncologyGazyva for the treatment of MN2023
2023-09-23PFIZER INC.$35,507Research paymentCash or cash equivalentPREVNAR 20 Biological, VACCINESA PHASE 4 STUDY USING A TESTNEGATIVE DESIGN TO EVALUATE THE EFFECTIVENESS OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE A2023
2023-09-22Genentech, Inc.$8,252Research paymentCash or cash equivalentSingle agent GDC 9545 vs endocrine monotherapy adjuvant treatment in HR eBC2023
2023-09-22PFIZER INC.$1,717Research paymentCash or cash equivalentPREVNAR 20 Biological, VACCINESA PHASE 4 STUDY USING A TESTNEGATIVE DESIGN TO EVALUATE THE EFFECTIVENESS OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE A2023
2023-09-22PFIZER INC.$1,500Research paymentCash or cash equivalentCOMIRNATY Biological, VACCINESA PHASE 3 MASTER PROTOCOL TO EVALUATE ADDITIONAL DOSES OF BNT162B2 IN HEALTHY INDIVIDUALS PREVIOUSLY VACCINATED WITH BNT2023
2023-09-22PFIZER INC.$1,200Research paymentCash or cash equivalentCOMIRNATY Biological, VACCINESA PHASE 3 MASTER PROTOCOL TO EVALUATE ADDITIONAL DOSES OF BNT162B2 IN HEALTHY INDIVIDUALS PREVIOUSLY VACCINATED WITH BNT2023
2023-09-20PFIZER INC.$14,420Research paymentCash or cash equivalentABRYSVO Biological, VACCINESA PHASE 3 STUDY TO EVALUATE THE EFFICACY IMMUNOGENICITY AND SAFETY OF RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNI2023
2023-09-14PFIZER INC.$71,985Research paymentCash or cash equivalentABRYSVO Biological, VACCINESA PHASE 3 STUDY TO EVALUATE THE EFFICACY IMMUNOGENICITY AND SAFETY OF RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNI2023
2023-09-06PFIZER INC.$6,796Research paymentCash or cash equivalentCOMIRNATY Biological, VACCINESA PHASE 3 MASTER PROTOCOL TO EVALUATE ADDITIONAL DOSES OF BNT162B2 IN HEALTHY INDIVIDUALS PREVIOUSLY VACCINATED WITH BNT2023
2023-09-02PFIZER INC.$9,047Research paymentCash or cash equivalentPREVNAR 20 Biological, VACCINESA PHASE 4 STUDY USING A TESTNEGATIVE DESIGN TO EVALUATE THE EFFECTIVENESS OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE A2023
2023-09-01PFIZER INC.$2,627Research paymentCash or cash equivalentLITFULO Drug, IMMUNOLOGYA PHASE 3 OPENLABEL MULTICENTER LONGTERM STUDY INVESTIGATING THE SAFETY AND EFFICACY OF PF06651600 IN ADULT AND ADOLESCE2023
2023-08-31PFIZER INC.$2,381Research paymentCash or cash equivalentCOMIRNATY Biological, VACCINESAN INTERVENTIONAL RANDOMIZED ACTIVECONTROLLED PHASE 23 STUDY TO INVESTIGATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY O2023
2023-08-30PFIZER INC.$8,400Research paymentCash or cash equivalentCOMIRNATY Biological, VACCINESPHASE 1 OPENLABEL DOSEFINDING STUDY TO EVALUATE SAFETY TOLERABILITY AND IMMUNOGENICITY AND PHASE 23 PLACEBOCONTROLLED OB2023
2023-08-30PFIZER INC.$378Research paymentCash or cash equivalentCOMIRNATY Biological, VACCINESPHASE 1 OPENLABEL DOSEFINDING STUDY TO EVALUATE SAFETY TOLERABILITY AND IMMUNOGENICITY AND PHASE 23 PLACEBOCONTROLLED OB2023
2023-08-28Genentech, Inc.$20,200Research paymentCash or cash equivalentA phase III trial of GDC 9545 in combination with palbo in HR HER2 neg 1L mBC2023
2023-08-26PFIZER INC.$19,350Research paymentCash or cash equivalentCOMIRNATY Biological, VACCINESA PHASE 3 MASTER PROTOCOL TO EVALUATE ADDITIONAL DOSES OF BNT162B2 IN HEALTHY INDIVIDUALS PREVIOUSLY VACCINATED WITH BNT2023
2023-08-24PFIZER INC.$30,932Research paymentCash or cash equivalentPREVNAR 20 Biological, VACCINESA PHASE 4 STUDY USING A TESTNEGATIVE DESIGN TO EVALUATE THE EFFECTIVENESS OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE A2023
2023-08-24PFIZER INC.$350Research paymentCash or cash equivalentCOMIRNATY Biological, VACCINESPHASE 1 OPENLABEL DOSEFINDING STUDY TO EVALUATE SAFETY TOLERABILITY AND IMMUNOGENICITY AND PHASE 23 PLACEBOCONTROLLED OB2023
2023-08-23PFIZER INC.$1,717Research paymentCash or cash equivalentPREVNAR 20 Biological, VACCINESA PHASE 4 STUDY USING A TESTNEGATIVE DESIGN TO EVALUATE THE EFFECTIVENESS OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE A2023
2023-08-23Genentech, Inc.$195Research paymentCash or cash equivalentMyTACTIC Targeting Actionable Mutation Study in Cancer US PIIa multicenter nonrandomized open LBL2023
2023-08-10PFIZER INC.$3,050Research paymentCash or cash equivalentCOMIRNATY Biological, VACCINESA PHASE 3 MASTER PROTOCOL TO EVALUATE ADDITIONAL DOSES OF BNT162B2 IN HEALTHY INDIVIDUALS PREVIOUSLY VACCINATED WITH BNT2023
2023-08-09Genentech, Inc.$12,108Research paymentCash or cash equivalentMyTACTIC Targeting Actionable Mutation Study in Cancer US PIIa multicenter nonrandomized open LBL2023
2023-08-08PFIZER INC.$30,674Research paymentCash or cash equivalentCOMIRNATY Biological, VACCINESPHASE 1 OPENLABEL DOSEFINDING STUDY TO EVALUATE SAFETY TOLERABILITY AND IMMUNOGENICITY AND PHASE 23 PLACEBOCONTROLLED OB2023
2023-08-08PFIZER INC.$10,130Research paymentCash or cash equivalentPREVNAR 20 Biological, VACCINESA PHASE 4 STUDY USING A TESTNEGATIVE DESIGN TO EVALUATE THE EFFECTIVENESS OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE A2023
2023-08-08PFIZER INC.$757Research paymentCash or cash equivalentCOMIRNATY Biological, VACCINESPHASE 1 OPENLABEL DOSEFINDING STUDY TO EVALUATE SAFETY TOLERABILITY AND IMMUNOGENICITY AND PHASE 23 PLACEBOCONTROLLED OB2023
2023-08-08PFIZER INC.$378Research paymentCash or cash equivalentCOMIRNATY Biological, VACCINESPHASE 1 OPENLABEL DOSEFINDING STUDY TO EVALUATE SAFETY TOLERABILITY AND IMMUNOGENICITY AND PHASE 23 PLACEBOCONTROLLED OB2023
2023-08-08PFIZER INC.$189Research paymentCash or cash equivalentA PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED2023
2023-08-05PFIZER INC.$1,500Research paymentCash or cash equivalentCOMIRNATY Biological, VACCINESAN INTERVENTIONAL RANDOMIZED ACTIVECONTROLLED PHASE 23 STUDY TO INVESTIGATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY O2023
2023-08-01Genentech, Inc.$850Research paymentCash or cash equivalentMyTACTIC Targeting Actionable Mutation Study in Cancer US PIIa multicenter nonrandomized open LBL2023
2023-07-28Genentech, Inc.$15,258Research paymentCash or cash equivalentGazyva Biological, BioOncologyGazyva for the treatment of MN2023
2023-07-28PFIZER INC.$7,728Research paymentCash or cash equivalentCOMIRNATY Biological, VACCINESPHASE 1 OPENLABEL DOSEFINDING STUDY TO EVALUATE SAFETY TOLERABILITY AND IMMUNOGENICITY AND PHASE 23 PLACEBOCONTROLLED OB2023
2023-07-28Genentech, Inc.$4,525Research paymentCash or cash equivalentGazyva Biological, BioOncologyGazyva for the treatment of MN2023
2023-07-28PFIZER INC.$1,015Research paymentCash or cash equivalentCOMIRNATY Biological, VACCINESPHASE 1 OPENLABEL DOSEFINDING STUDY TO EVALUATE SAFETY TOLERABILITY AND IMMUNOGENICITY AND PHASE 23 PLACEBOCONTROLLED OB2023
2023-07-26PFIZER INC.$14,430Research paymentCash or cash equivalentPREVNAR 20 Biological, VACCINESA PHASE 4 STUDY USING A TESTNEGATIVE DESIGN TO EVALUATE THE EFFECTIVENESS OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE A2023
2023-07-26PFIZER INC.$2,400Research paymentCash or cash equivalentCOMIRNATY Biological, VACCINESA PHASE 3 MASTER PROTOCOL TO EVALUATE ADDITIONAL DOSES OF BNT162B2 IN HEALTHY INDIVIDUALS PREVIOUSLY VACCINATED WITH BNT2023
2023-07-25PFIZER INC.$8,243Research paymentCash or cash equivalentPREVNAR 20 Biological, VACCINESA PHASE 4 STUDY USING A TESTNEGATIVE DESIGN TO EVALUATE THE EFFECTIVENESS OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE A2023
2023-07-25Genentech, Inc.$5,243Research paymentCash or cash equivalentA phase III trial of GDC 9545 in combination with palbo in HR HER2 neg 1L mBC2023
2023-07-20PFIZER INC.$5,100Research paymentCash or cash equivalentCOMIRNATY Biological, VACCINESPHASE 1 OPENLABEL DOSEFINDING STUDY TO EVALUATE SAFETY TOLERABILITY AND IMMUNOGENICITY AND PHASE 23 PLACEBOCONTROLLED OB2023
2023-07-20PFIZER INC.$2,328Research paymentCash or cash equivalentCOMIRNATY Biological, VACCINESPHASE 1 OPENLABEL DOSEFINDING STUDY TO EVALUATE SAFETY TOLERABILITY AND IMMUNOGENICITY AND PHASE 23 PLACEBOCONTROLLED OB2023
2023-07-19PFIZER INC.$34,632Research paymentCash or cash equivalentCOMIRNATY Biological, VACCINESA PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENIC2023
2023-07-19Genentech, Inc.$5,085Research paymentCash or cash equivalentCellCept Drug, Virology & Specialty CareRandomised Double blind study to evaluate safety and efficacy of Obinutuzumab in Class III and IV LN2023
2023-07-19PFIZER INC.$1,200Research paymentCash or cash equivalentCOMIRNATY Biological, VACCINESA PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENIC2023
2023-07-15PFIZER INC.$26,785Research paymentCash or cash equivalentCOMIRNATY Biological, VACCINESAN INTERVENTIONAL RANDOMIZED ACTIVECONTROLLED PHASE 23 STUDY TO INVESTIGATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY O2023
2023-07-15PFIZER INC.$600Research paymentCash or cash equivalentPREVNAR 20 Biological, VACCINESA PHASE 3 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20VALENT PNEUMOCOCCAL CONJUGATE VA2023
2023-07-14Genentech, Inc.$32,500Research paymentCash or cash equivalentMyTACTIC Targeting Actionable Mutation Study in Cancer US PIIa multicenter nonrandomized open LBL2023
2023-07-14Genentech, Inc.$13,294Research paymentCash or cash equivalentMyTACTIC Targeting Actionable Mutation Study in Cancer US PIIa multicenter nonrandomized open LBL2023
2023-07-14Genentech, Inc.$4,200Research paymentCash or cash equivalentMyTACTIC Targeting Actionable Mutation Study in Cancer US PIIa multicenter nonrandomized open LBL2023
2023-07-14Genentech, Inc.$2,400Research paymentCash or cash equivalentMyTACTIC Targeting Actionable Mutation Study in Cancer US PIIa multicenter nonrandomized open LBL2023
2023-07-14Genentech, Inc.$2,100Research paymentCash or cash equivalentMyTACTIC Targeting Actionable Mutation Study in Cancer US PIIa multicenter nonrandomized open LBL2023
2023-07-13PFIZER INC.$8,100Research paymentCash or cash equivalentCOMIRNATY Biological, VACCINESA PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENIC2023
2023-07-13PFIZER INC.$3,750Research paymentCash or cash equivalentCOMIRNATY Biological, VACCINESA PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENIC2023
2023-07-12PFIZER INC.$5,792Research paymentCash or cash equivalentABRYSVO Biological, VACCINESA PHASE 3 STUDY TO EVALUATE THE EFFICACY IMMUNOGENICITY AND SAFETY OF RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNI2023
2023-07-11Genentech, Inc.$143,917Research paymentCash or cash equivalent2023
2023-07-11PFIZER INC.$22,457Research paymentCash or cash equivalentPREVNAR 20 Biological, VACCINESA PHASE 4 STUDY USING A TESTNEGATIVE DESIGN TO EVALUATE THE EFFECTIVENESS OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE A2023
2023-07-10Genentech, Inc.$15,610Research paymentCash or cash equivalentA phase III trial of GDC 9545 in combination with palbo in HR HER2 neg 1L mBC2023
2023-07-10Genentech, Inc.$12,705Research paymentCash or cash equivalentA phase III trial of GDC 9545 in combination with palbo in HR HER2 neg 1L mBC2023
2023-07-06Genentech, Inc.$80,000Research paymentCash or cash equivalent2023
2023-07-04PFIZER INC.$4,924Research paymentCash or cash equivalentABRYSVO Biological, VACCINESA PHASE 3 STUDY TO EVALUATE THE EFFICACY IMMUNOGENICITY AND SAFETY OF RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNI2023
2023-07-04PFIZER INC.$1,500Research paymentCash or cash equivalentA PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED2023
2023-06-30PFIZER INC.$757Research paymentCash or cash equivalentCOMIRNATY Biological, VACCINESPHASE 1 OPENLABEL DOSEFINDING STUDY TO EVALUATE SAFETY TOLERABILITY AND IMMUNOGENICITY AND PHASE 23 PLACEBOCONTROLLED OB2023
2023-06-30PFIZER INC.$757Research paymentCash or cash equivalentCOMIRNATY Biological, VACCINESPHASE 1 OPENLABEL DOSEFINDING STUDY TO EVALUATE SAFETY TOLERABILITY AND IMMUNOGENICITY AND PHASE 23 PLACEBOCONTROLLED OB2023
2023-06-28PFIZER INC.$2,148Research paymentCash or cash equivalentA PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED2023
2023-06-27Genentech, Inc.$1,143Research paymentCash or cash equivalent2023
2023-06-24PFIZER INC.$20,709Research paymentCash or cash equivalentPREVNAR 20 Biological, VACCINESA PHASE 4 STUDY USING A TESTNEGATIVE DESIGN TO EVALUATE THE EFFECTIVENESS OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE A2023
2023-06-24PFIZER INC.$9,028Research paymentCash or cash equivalentABRYSVO Biological, VACCINESA PHASE 3 STUDY TO EVALUATE THE EFFICACY IMMUNOGENICITY AND SAFETY OF RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNI2023
2023-06-23PFIZER INC.$12,000Research paymentCash or cash equivalentPREVNAR 20 Biological, VACCINESA PHASE 4 STUDY USING A TESTNEGATIVE DESIGN TO EVALUATE THE EFFECTIVENESS OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE A2023
2023-06-22Genentech, Inc.$118,638Research paymentCash or cash equivalent2023
2023-06-21PFIZER INC.$378Research paymentCash or cash equivalentA PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED2023
2023-06-20PFIZER INC.$4,650Research paymentCash or cash equivalentCOMIRNATY Biological, VACCINESA PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENIC2023
2023-06-16PFIZER INC.$1,500Research paymentCash or cash equivalentCOMIRNATY Biological, VACCINESA PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENIC2023
2023-06-15PFIZER INC.$1,135Research paymentCash or cash equivalentCOMIRNATY Biological, VACCINESPHASE 1 OPENLABEL DOSEFINDING STUDY TO EVALUATE SAFETY TOLERABILITY AND IMMUNOGENICITY AND PHASE 23 PLACEBOCONTROLLED OB2023
2023-06-15PFIZER INC.$756Research paymentCash or cash equivalentA PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED2023
2023-06-15PFIZER INC.$378Research paymentCash or cash equivalentCOMIRNATY Biological, VACCINESPHASE 1 OPENLABEL DOSEFINDING STUDY TO EVALUATE SAFETY TOLERABILITY AND IMMUNOGENICITY AND PHASE 23 PLACEBOCONTROLLED OB2023
2023-06-14PFIZER INC.$24,700Research paymentCash or cash equivalentCOMIRNATY Biological, VACCINESA PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENIC2023
2023-06-13Genentech, Inc.$16,100Research paymentCash or cash equivalentAvastin Biological, BioOncologyA PHASE III OPEN LABEL RANDOMIZED STUDY EVALUATING THE EFFICACY AND SAFETY OF ATEZOLIZUMAB IN COMB2023
2023-06-13PFIZER INC.$2,268Research paymentCash or cash equivalentA PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED2023
2023-06-07PFIZER INC.$18,500Research paymentCash or cash equivalentCOMIRNATY Biological, VACCINESA PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENIC2023
2023-06-07PFIZER INC.$12,601Research paymentCash or cash equivalentCOMIRNATY Biological, VACCINESA PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENIC2023
2023-06-06PFIZER INC.$757Research paymentCash or cash equivalentCOMIRNATY Biological, VACCINESPHASE 1 OPENLABEL DOSEFINDING STUDY TO EVALUATE SAFETY TOLERABILITY AND IMMUNOGENICITY AND PHASE 23 PLACEBOCONTROLLED OB2023
2023-06-03PFIZER INC.$14,337Research paymentCash or cash equivalentPREVNAR 20 Biological, VACCINESA PHASE 4 STUDY USING A TESTNEGATIVE DESIGN TO EVALUATE THE EFFECTIVENESS OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE A2023
2023-06-03PFIZER INC.$520Research paymentCash or cash equivalentCOMIRNATY Biological, VACCINESA PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENIC2023
2023-06-02PFIZER INC.$1,890Research paymentCash or cash equivalentA PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED2023
2023-06-01Genentech, Inc.$724,800Research paymentCash or cash equivalentAvastin Biological, BioOncologyA PHASE III MULTICENTER RANDOMIZED PLACEBO CONTROLLED STUDY OF ATEZOLIZUMAB VERSUS PLACEBO IN COM2023
2023-06-01PFIZER INC.$16,815Research paymentCash or cash equivalentLITFULO Drug, IMMUNOLOGYA PHASE 3 OPENLABEL MULTICENTER LONGTERM STUDY INVESTIGATING THE SAFETY AND EFFICACY OF PF06651600 IN ADULT AND ADOLESCE2023
2023-05-26PFIZER INC.$33,072Research paymentCash or cash equivalentCOMIRNATY Biological, VACCINESPHASE 1 OPENLABEL DOSEFINDING STUDY TO EVALUATE SAFETY TOLERABILITY AND IMMUNOGENICITY AND PHASE 23 PLACEBOCONTROLLED OB2023
2023-05-26PFIZER INC.$22,048Research paymentCash or cash equivalentCOMIRNATY Biological, VACCINESPHASE 1 OPENLABEL DOSEFINDING STUDY TO EVALUATE SAFETY TOLERABILITY AND IMMUNOGENICITY AND PHASE 23 PLACEBOCONTROLLED OB2023
2023-05-26PFIZER INC.$16,536Research paymentCash or cash equivalentCOMIRNATY Biological, VACCINESPHASE 1 OPENLABEL DOSEFINDING STUDY TO EVALUATE SAFETY TOLERABILITY AND IMMUNOGENICITY AND PHASE 23 PLACEBOCONTROLLED OB2023
2023-05-26PFIZER INC.$5,204Research paymentCash or cash equivalentCOMIRNATY Biological, VACCINESA PHASE 3 MASTER PROTOCOL TO EVALUATE ADDITIONAL DOSES OF BNT162B2 IN HEALTHY INDIVIDUALS PREVIOUSLY VACCINATED WITH BNT2023
2023-05-25PFIZER INC.$66,484Research paymentCash or cash equivalentABRYSVO Biological, VACCINESA PHASE 3 STUDY TO EVALUATE THE EFFICACY IMMUNOGENICITY AND SAFETY OF RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNI2023
2023-05-25PFIZER INC.$4,779Research paymentCash or cash equivalentPREVNAR 20 Biological, VACCINESA PHASE 4 STUDY USING A TESTNEGATIVE DESIGN TO EVALUATE THE EFFECTIVENESS OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE A2023
2023-05-25PFIZER INC.$3,900Research paymentCash or cash equivalentA RANDOMIZED OPEN LABEL ACTIVE CONTROLLED SAFETY AND DESCRIPTIVE EFFICACY STUDY IN PEDIATRIC SUBJECTS REQUIRING ANTICOAG2023
2023-05-24PFIZER INC.$54,929Research paymentCash or cash equivalentCOMIRNATY Biological, VACCINESA PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENIC2023
2023-05-24PFIZER INC.$8,329Research paymentCash or cash equivalentA PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED2023
2023-05-24PFIZER INC.$2,605Research paymentCash or cash equivalentLITFULO Drug, IMMUNOLOGYA PHASE 3 OPENLABEL MULTICENTER LONGTERM STUDY INVESTIGATING THE SAFETY AND EFFICACY OF PF06651600 IN ADULT AND ADOLESCE2023
2023-05-23PFIZER INC.$500Research paymentCash or cash equivalentCOMIRNATY Biological, VACCINESA PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENIC2023
2023-05-18Genentech, Inc.$12,000Research paymentCash or cash equivalentSingle agent GDC 9545 vs endocrine monotherapy adjuvant treatment in HR eBC2023
2023-05-18PFIZER INC.$5,414Research paymentCash or cash equivalentCOMIRNATY Biological, VACCINESA PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENIC2023
2023-05-18Genentech, Inc.$3,500Research paymentCash or cash equivalentSingle agent GDC 9545 vs endocrine monotherapy adjuvant treatment in HR eBC2023
2023-05-13PFIZER INC.$637Research paymentCash or cash equivalentCOMIRNATY Biological, VACCINESPHASE 1 OPENLABEL DOSEFINDING STUDY TO EVALUATE SAFETY TOLERABILITY AND IMMUNOGENICITY AND PHASE 23 PLACEBOCONTROLLED OB2023
2023-05-12PFIZER INC.$9,750Research paymentCash or cash equivalentCOMIRNATY Biological, VACCINESA PHASE 3 MASTER PROTOCOL TO EVALUATE ADDITIONAL DOSES OF BNT162B2 IN HEALTHY INDIVIDUALS PREVIOUSLY VACCINATED WITH BNT2023
2023-05-09PFIZER INC.$7,318Research paymentCash or cash equivalentA PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED2023
2023-05-01Genentech, Inc.$1,043Research paymentCash or cash equivalentPH III open label study atezo vs BSC following adjuvant chemo in stage IB IIIA NSCLC2023
2023-04-29PFIZER INC.$11,414Research paymentCash or cash equivalentCOMIRNATY Biological, VACCINESPHASE 1 OPENLABEL DOSEFINDING STUDY TO EVALUATE SAFETY TOLERABILITY AND IMMUNOGENICITY AND PHASE 23 PLACEBOCONTROLLED OB2023
2023-04-29PFIZER INC.$5,000Research paymentCash or cash equivalentCOMIRNATY Biological, VACCINESA PHASE 3 MASTER PROTOCOL TO EVALUATE ADDITIONAL DOSES OF BNT162B2 IN HEALTHY INDIVIDUALS PREVIOUSLY VACCINATED WITH BNT2023
2023-04-28PFIZER INC.$2,328Research paymentCash or cash equivalentCOMIRNATY Biological, VACCINESAN INTERVENTIONAL RANDOMIZED ACTIVECONTROLLED PHASE 23 STUDY TO INVESTIGATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY O2023
2023-04-26PFIZER INC.$10,972Research paymentCash or cash equivalentCOMIRNATY Biological, VACCINESPHASE 1 OPENLABEL DOSEFINDING STUDY TO EVALUATE SAFETY TOLERABILITY AND IMMUNOGENICITY AND PHASE 23 PLACEBOCONTROLLED OB2023
2023-04-26PFIZER INC.$3,822Research paymentCash or cash equivalentCOMIRNATY Biological, VACCINESPHASE 1 OPENLABEL DOSEFINDING STUDY TO EVALUATE SAFETY TOLERABILITY AND IMMUNOGENICITY AND PHASE 23 PLACEBOCONTROLLED OB2023
2023-04-25Genentech, Inc.$8,651Research paymentCash or cash equivalentA phase III trial of GDC 9545 in combination with palbo in HR HER2 neg 1L mBC2023
2023-04-25Genentech, Inc.$1,073Research paymentCash or cash equivalentCellCept Drug, Virology & Specialty CareRandomised Double blind study to evaluate safety and efficacy of Obinutuzumab in Class III and IV LN2023
2023-04-25Genentech, Inc.$524Research paymentCash or cash equivalentA phase III trial of GDC 9545 in combination with palbo in HR HER2 neg 1L mBC2023
2023-04-20PFIZER INC.$6,277Research paymentCash or cash equivalentCOMIRNATY Biological, VACCINESAN INTERVENTIONAL RANDOMIZED ACTIVECONTROLLED PHASE 23 STUDY TO INVESTIGATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY O2023
2023-04-19PFIZER INC.$1,251Research paymentCash or cash equivalentCOMIRNATY Biological, VACCINESPHASE 1 OPENLABEL DOSEFINDING STUDY TO EVALUATE SAFETY TOLERABILITY AND IMMUNOGENICITY AND PHASE 23 PLACEBOCONTROLLED OB2023
2023-04-12PFIZER INC.$17,000Research paymentCash or cash equivalentPREVNAR 20 Biological, VACCINESA PHASE 4 STUDY USING A TESTNEGATIVE DESIGN TO EVALUATE THE EFFECTIVENESS OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE A2023
2023-04-04PFIZER INC.$4,500Research paymentCash or cash equivalentA PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED2023
2023-04-01PFIZER INC.$36,865Research paymentCash or cash equivalentCOMIRNATY Biological, VACCINESAN INTERVENTIONAL RANDOMIZED ACTIVECONTROLLED PHASE 23 STUDY TO INVESTIGATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY O2023
2023-03-30Genentech, Inc.$1,240Research paymentCash or cash equivalentHerceptin Biological, BioOncologyChemo trastuzumab vs chemo trastuzumab pertuzumab2023
2023-03-30Genentech, Inc.$582Research paymentCash or cash equivalentHerceptin Biological, BioOncologyChemo trastuzumab vs chemo trastuzumab pertuzumab2023
2023-03-30Genentech, Inc.$582Research paymentCash or cash equivalentHerceptin Biological, BioOncologyChemo trastuzumab vs chemo trastuzumab pertuzumab2023
2023-03-30Genentech, Inc.$582Research paymentCash or cash equivalentHerceptin Biological, BioOncologyChemo trastuzumab vs chemo trastuzumab pertuzumab2023
2023-03-30Genentech, Inc.$150Research paymentCash or cash equivalentHerceptin Biological, BioOncologyChemo trastuzumab vs chemo trastuzumab pertuzumab2023
2023-03-30Genentech, Inc.$75Research paymentCash or cash equivalentHerceptin Biological, BioOncologyChemo trastuzumab vs chemo trastuzumab pertuzumab2023
2023-03-29PFIZER INC.$2,000Research paymentCash or cash equivalentCOMIRNATY Biological, VACCINESA PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENIC2023
2023-03-28PFIZER INC.$11,924Research paymentCash or cash equivalentCOMIRNATY Biological, VACCINESA PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENIC2023
2023-03-23Genentech, Inc.$11,918Research paymentCash or cash equivalentCellCept Drug, Virology & Specialty CareRandomised Double blind study to evaluate safety and efficacy of Obinutuzumab in Class III and IV LN2023
2023-03-23PFIZER INC.$9,928Research paymentCash or cash equivalentTALZENNA Drug, ONCOLOGYA PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY OF TALAZOPARIB WITH ENZALUTAMIDE IN METASTATIC CASTRATIONRESIST2023
2023-03-23PFIZER INC.$8,051Research paymentCash or cash equivalentABRYSVO Biological, VACCINESA PHASE 3 STUDY TO EVALUATE THE EFFICACY IMMUNOGENICITY AND SAFETY OF RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNI2023
2023-03-22PFIZER INC.$1,979Research paymentCash or cash equivalentABRYSVO Biological, VACCINESA PHASE 3 STUDY TO EVALUATE THE EFFICACY IMMUNOGENICITY AND SAFETY OF RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNI2023
2023-03-22PFIZER INC.$1,600Research paymentCash or cash equivalentCOMIRNATY Biological, VACCINESA PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENIC2023
2023-03-21PFIZER INC.$10,216Research paymentCash or cash equivalentCOMIRNATY Biological, VACCINESAN INTERVENTIONAL RANDOMIZED ACTIVECONTROLLED PHASE 23 STUDY TO INVESTIGATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY O2023
2023-03-14Genentech, Inc.$3,099Research paymentCash or cash equivalentMyTACTIC Targeting Actionable Mutation Study in Cancer US PIIa multicenter nonrandomized open LBL2023
2023-03-11PFIZER INC.$13,015Research paymentCash or cash equivalentCOMIRNATY Biological, VACCINESA PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENIC2023
2023-03-11PFIZER INC.$7,658Research paymentCash or cash equivalentCOMIRNATY Biological, VACCINESA PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENIC2023
2023-03-10PFIZER INC.$5,108Research paymentCash or cash equivalentCOMIRNATY Biological, VACCINESAN INTERVENTIONAL RANDOMIZED ACTIVECONTROLLED PHASE 23 STUDY TO INVESTIGATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY O2023
2023-03-10PFIZER INC.$4,765Research paymentCash or cash equivalentCOMIRNATY Biological, VACCINESA PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENIC2023
2023-03-08PFIZER INC.$364Research paymentCash or cash equivalentA PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED2023
2023-03-02Genentech, Inc.$20,126Research paymentCash or cash equivalentMyTACTIC Targeting Actionable Mutation Study in Cancer US PIIa multicenter nonrandomized open LBL2023
2023-03-02Genentech, Inc.$12,000Research paymentCash or cash equivalentMyTACTIC Targeting Actionable Mutation Study in Cancer US PIIa multicenter nonrandomized open LBL2023
2023-03-02Genentech, Inc.$4,000Research paymentCash or cash equivalentMyTACTIC Targeting Actionable Mutation Study in Cancer US PIIa multicenter nonrandomized open LBL2023
2023-03-02Genentech, Inc.$2,000Research paymentCash or cash equivalentMyTACTIC Targeting Actionable Mutation Study in Cancer US PIIa multicenter nonrandomized open LBL2023
2023-03-02Genentech, Inc.$1,875Research paymentCash or cash equivalentMyTACTIC Targeting Actionable Mutation Study in Cancer US PIIa multicenter nonrandomized open LBL2023
2023-03-02Genentech, Inc.$1,675Research paymentCash or cash equivalentMyTACTIC Targeting Actionable Mutation Study in Cancer US PIIa multicenter nonrandomized open LBL2023
2023-03-02PFIZER INC.$378Research paymentCash or cash equivalentCOMIRNATY Biological, VACCINESPHASE 1 OPENLABEL DOSEFINDING STUDY TO EVALUATE SAFETY TOLERABILITY AND IMMUNOGENICITY AND PHASE 23 PLACEBOCONTROLLED OB2023
2023-02-27PFIZER INC.$369,170Research paymentCash or cash equivalentIBRANCE Drug, ONCOLOGYDESCRIBE CLINICAL CHARACTERISTICS TREATMENT PATTERNS AND INCIDENCE OF DISEASE RECURRENCE AMONG FEMALE PATIENTS DIAGNOSED2023
2023-02-25PFIZER INC.$12,028Research paymentCash or cash equivalentA PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED2023
2023-02-21Genentech, Inc.$72,670Research paymentCash or cash equivalentMyTACTIC Targeting Actionable Mutation Study in Cancer US PIIa multicenter nonrandomized open LBL2023
2023-02-21Genentech, Inc.$1,250Research paymentCash or cash equivalentMyTACTIC Targeting Actionable Mutation Study in Cancer US PIIa multicenter nonrandomized open LBL2023
2023-02-21Genentech, Inc.$750Research paymentCash or cash equivalentMyTACTIC Targeting Actionable Mutation Study in Cancer US PIIa multicenter nonrandomized open LBL2023
2023-02-21Genentech, Inc.$614Research paymentCash or cash equivalentMyTACTIC Targeting Actionable Mutation Study in Cancer US PIIa multicenter nonrandomized open LBL2023
2023-02-14PFIZER INC.$36,506Research paymentCash or cash equivalentABRYSVO Biological, VACCINESA PHASE 3 STUDY TO EVALUATE THE EFFICACY IMMUNOGENICITY AND SAFETY OF RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNI2023
2023-02-14PFIZER INC.$7,202Research paymentCash or cash equivalentCOMIRNATY Biological, VACCINESAN INTERVENTIONAL RANDOMIZED ACTIVECONTROLLED PHASE 23 STUDY TO INVESTIGATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY O2023
2023-02-14PFIZER INC.$2,627Research paymentCash or cash equivalentLITFULO Drug, IMMUNOLOGYA PHASE 3 OPENLABEL MULTICENTER LONGTERM STUDY INVESTIGATING THE SAFETY AND EFFICACY OF PF06651600 IN ADULT AND ADOLESCE2023
2023-02-04PFIZER INC.$1,620Research paymentCash or cash equivalentA PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED2023
2023-02-03PFIZER INC.$4,926Research paymentCash or cash equivalentTALZENNA Drug, ONCOLOGYA PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY OF TALAZOPARIB WITH ENZALUTAMIDE IN METASTATIC CASTRATIONRESIST2023
2023-02-03PFIZER INC.$757Research paymentCash or cash equivalentCOMIRNATY Biological, VACCINESPHASE 1 OPENLABEL DOSEFINDING STUDY TO EVALUATE SAFETY TOLERABILITY AND IMMUNOGENICITY AND PHASE 23 PLACEBOCONTROLLED OB2023
2023-02-03PFIZER INC.$378Research paymentCash or cash equivalentCOMIRNATY Biological, VACCINESPHASE 1 OPENLABEL DOSEFINDING STUDY TO EVALUATE SAFETY TOLERABILITY AND IMMUNOGENICITY AND PHASE 23 PLACEBOCONTROLLED OB2023
2023-02-02Genentech, Inc.$80,000Research paymentCash or cash equivalent2023
2023-02-02Genentech, Inc.$80,000Research paymentCash or cash equivalent2023
2023-02-02Genentech, Inc.$38,360Research paymentCash or cash equivalentMyTACTIC Targeting Actionable Mutation Study in Cancer US PIIa multicenter nonrandomized open LBL2023
2023-02-02Genentech, Inc.$6,659Research paymentCash or cash equivalentMyTACTIC Targeting Actionable Mutation Study in Cancer US PIIa multicenter nonrandomized open LBL2023
2023-01-31PFIZER INC.$16,352Research paymentCash or cash equivalentCOMIRNATY Biological, VACCINESAN INTERVENTIONAL RANDOMIZED ACTIVECONTROLLED PHASE 23 STUDY TO INVESTIGATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY O2023
2023-01-28PFIZER INC.$378Research paymentCash or cash equivalentCOMIRNATY Biological, VACCINESPHASE 1 OPENLABEL DOSEFINDING STUDY TO EVALUATE SAFETY TOLERABILITY AND IMMUNOGENICITY AND PHASE 23 PLACEBOCONTROLLED OB2023
2023-01-27Genentech, Inc.$5,133Research paymentCash or cash equivalentA phase III trial of GDC 9545 in combination with palbo in HR HER2 neg 1L mBC2023

The latest 200 records of 215.

CMS Open Payments: payments and transfers of value that drug and medical device makers and group purchasing organizations report to Medicare, program years 2019 on, as published by CMS (general, research and ownership records; refreshed by CMS each June and January). Links to other records on this site are by name (and state) only.

The area Census

Contra Costa CountyAntioch city

County outline, the place (blue), the tract (orange) and the ZIP center (dot).

In Antioch, CA, county Contra Costa County, CA, state California; placed by its city name.

MeasurePlace (city or town)
Antioch, CA
County
Contra Costa County, CA
State
California
Population B01003116,4771,165,01239,287,377
Population, 2020 census P1115,2911,165,92739,538,223
Median age B0100238.440.537.9
Under 18 B0100122.8%22.0%22.0%
65 and over B0100114.3%17.1%15.7%
Households B1100137,381414,41713,548,091
Foreign born B0500224.6%26.6%27.0%
Median household income B19013$97,465$127,229$99,122
Median family income B19113$109,115$148,679$113,346
Per capita income B19301$41,008$62,927$49,513
Poverty rate B1700111.4%8.4%12.0%
Unemployment rate B230257.4%6.5%6.6%
Civilian labor force B2302560,709608,62020,068,466
Mean commute (minutes) B0801342.035.328.7
Bachelor's degree or higher B1500323.9%45.2%37.1%
Housing units B2500138,629429,26014,644,735
Owner-occupied B2500363.6%68.0%55.9%
Renters B2500336.4%32.0%44.1%
Median home value B25077$629,700$866,800$734,700
Median gross rent B25064$2,278$2,375$2,036
White, not Hispanic B0300223.4%38.1%33.8%
Black B0300218.2%7.9%5.2%
Hispanic or Latino B0300235.6%27.6%40.2%
Asian B0300213.9%18.6%15.3%
American Indian and Alaska Native B030020.5%0.2%0.3%

Economy now FRED unemployment 5.1% in Sep 2026 (5.5% a year earlier); per capita personal income $90,957 in 2025, up 30% in five years (+4.3% after inflation); Unemployment rate: 5.5% in Sep 2016 to 5.1% in Sep 2026; low 3.8%, high 16.1% the state; Source: FRED, Federal Reserve Bank of St. Louis.

Data: IPUMS NHGIS (ACS 2020-2024 and the 2020 census); each figure links to its table for that area at data.census.gov. Records are placed by ZIP code and city name, not street address. More: everything FURP has in Antioch, CA.

Comments

Anonymous: no account or email. Up to 2,000 characters, at most one link. Comments are checked automatically; some wait for review.